Incyte Corporation (INCY)
USD 59.22
(4.13%)
USD 59.22
(4.13%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 919.42 Million USD | 43.26% |
| 2022 | 599.63 Million USD | 3.33% |
| 2021 | 630.19 Million USD | 381.53% |
| 2020 | -178.23 Million USD | -145.81% |
| 2019 | 475.65 Million USD | 153.2% |
| 2018 | 209.83 Million USD | 185.64% |
| 2017 | -253.21 Million USD | -230.99% |
| 2016 | 204.57 Million USD | 188.94% |
| 2015 | 98.04 Million USD | 4071.11% |
| 2014 | 39.95 Million USD | 90.16% |
| 2013 | -14.98 Million USD | -872.91% |
| 2012 | 31.89 Million USD | 101.34% |
| 2011 | -115.73 Million USD | -893.83% |
| 2010 | 35.96 Million USD | 118.08% |
| 2009 | -123.07 Million USD | 31.89% |
| 2008 | -146.21 Million USD | -101.37% |
| 2007 | -72.31 Million USD | 2.1% |
| 2006 | -76.86 Million USD | 20.12% |
| 2005 | -92.59 Million USD | 30.74% |
| 2004 | -132.05 Million USD | -175.7% |
| 2003 | -149.29 Million USD | -30.86% |
| 2002 | -110.51 Million USD | -131.39% |
| 2001 | -17.03 Million USD | 548.0% |
| 2000 | -27.74 Million USD | -901.97% |
| 1999 | -2.3 Million USD | -90.91% |
| 1998 | 30 Million USD | 159.29% |
| 1997 | 14 Million USD | 976.92% |
| 1996 | -2.4 Million USD | 113.54% |
| 1995 | -8.1 Million USD | 19.33% |
| 1994 | -11.2 Million USD | -153.19% |
| 1993 | -4.5 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -455.18 Million USD | -421.59% |
| 2024 Q3 | 179.81 Million USD | 148.99% |
| 2024 Q1 | 158.13 Million USD | -61.11% |
| 2023 Q1 | 63.83 Million USD | -47.27% |
| 2023 FY | - USD | 43.26% |
| 2023 Q4 | 274.52 Million USD | 5.32% |
| 2023 Q2 | 265.11 Million USD | 315.29% |
| 2023 Q3 | 260.65 Million USD | -1.69% |
| 2022 FY | - USD | 3.33% |
| 2022 Q1 | 124.18 Million USD | 5.13% |
| 2022 Q2 | 258.26 Million USD | 107.97% |
| 2022 Q3 | 144.68 Million USD | -43.98% |
| 2022 Q4 | 121.07 Million USD | -16.32% |
| 2021 FY | - USD | 381.53% |
| 2021 Q4 | 118.12 Million USD | -53.67% |
| 2021 Q2 | 164.31 Million USD | 59.66% |
| 2021 Q3 | 254.95 Million USD | 55.16% |
| 2021 Q1 | 102.91 Million USD | -40.38% |
| 2020 Q4 | 172.63 Million USD | 469.73% |
| 2020 FY | - USD | -145.81% |
| 2020 Q1 | -635.61 Million USD | -657.67% |
| 2020 Q2 | 254.23 Million USD | 140.0% |
| 2020 Q3 | 30.3 Million USD | -88.08% |
| 2019 Q1 | 90.11 Million USD | -10.53% |
| 2019 Q4 | 113.97 Million USD | -23.79% |
| 2019 FY | - USD | 153.2% |
| 2019 Q3 | 149.55 Million USD | 11.9% |
| 2019 Q2 | 133.65 Million USD | 48.32% |
| 2018 Q4 | 100.71 Million USD | 68.24% |
| 2018 FY | - USD | 185.64% |
| 2018 Q3 | 59.86 Million USD | -45.5% |
| 2018 Q1 | -42.53 Million USD | 63.44% |
| 2018 Q2 | 109.85 Million USD | 358.24% |
| 2017 FY | - USD | -230.99% |
| 2017 Q1 | -109.71 Million USD | -320.26% |
| 2017 Q2 | 30.75 Million USD | 128.03% |
| 2017 Q3 | 16.11 Million USD | -47.61% |
| 2017 Q4 | -116.35 Million USD | -822.25% |
| 2016 Q3 | 48.44 Million USD | -20.39% |
| 2016 Q2 | 60.84 Million USD | 25.23% |
| 2016 FY | - USD | 188.94% |
| 2016 Q4 | 49.81 Million USD | 2.83% |
| 2016 Q1 | 48.58 Million USD | -26.79% |
| 2015 Q4 | 66.36 Million USD | 370.6% |
| 2015 Q3 | 14.1 Million USD | 181.16% |
| 2015 Q1 | 6.53 Million USD | 126.45% |
| 2015 FY | - USD | 4071.11% |
| 2015 Q2 | 5.01 Million USD | -23.19% |
| 2014 FY | - USD | 90.16% |
| 2014 Q4 | -24.68 Million USD | -130.59% |
| 2014 Q3 | 80.69 Million USD | 614.04% |
| 2014 Q2 | -15.69 Million USD | 29.28% |
| 2014 Q1 | -22.2 Million USD | -41.89% |
| 2013 FY | - USD | -872.91% |
| 2013 Q2 | 25.61 Million USD | 567.81% |
| 2013 Q1 | 3.83 Million USD | -87.47% |
| 2013 Q4 | -15.64 Million USD | -90.11% |
| 2013 Q3 | -8.23 Million USD | -132.13% |
| 2012 FY | - USD | 101.34% |
| 2012 Q2 | 15.53 Million USD | 157.74% |
| 2012 Q1 | -26.9 Million USD | 27.97% |
| 2012 Q4 | 30.62 Million USD | 1308.09% |
| 2012 Q3 | -2.53 Million USD | -116.32% |
| 2011 Q3 | -35.18 Million USD | -2.48% |
| 2011 Q1 | -9.32 Million USD | -117.73% |
| 2011 Q4 | -37.34 Million USD | -6.13% |
| 2011 FY | - USD | -893.83% |
| 2011 Q2 | -34.33 Million USD | -268.28% |
| 2010 Q4 | 52.57 Million USD | 419.3% |
| 2010 Q2 | 19.5 Million USD | 247.36% |
| 2010 Q1 | -13.23 Million USD | -1964.65% |
| 2010 FY | - USD | 118.08% |
| 2010 Q3 | -16.46 Million USD | -184.4% |
| 2009 Q2 | -32.73 Million USD | -3.15% |
| 2009 Q4 | 710 Thousand USD | 103.24% |
| 2009 FY | - USD | 31.89% |
| 2009 Q1 | -31.73 Million USD | 16.14% |
| 2009 Q3 | -21.92 Million USD | 33.04% |
| 2008 FY | - USD | -101.37% |
| 2008 Q1 | -32.59 Million USD | -38.52% |
| 2008 Q2 | -38.34 Million USD | -17.67% |
| 2008 Q3 | -36.74 Million USD | 4.19% |
| 2008 Q4 | -37.84 Million USD | -2.99% |
| 2007 Q1 | -16.87 Million USD | 38.27% |
| 2007 Q4 | -23.52 Million USD | -22.2% |
| 2007 Q3 | -19.25 Million USD | -47.29% |
| 2007 Q2 | -13.07 Million USD | 22.51% |
| 2007 FY | - USD | 2.1% |
| 2006 Q2 | -15.01 Million USD | 26.37% |
| 2006 Q3 | -14.42 Million USD | 3.91% |
| 2006 FY | - USD | 20.12% |
| 2006 Q4 | -27.32 Million USD | -89.4% |
| 2006 Q1 | -20.39 Million USD | 18.1% |
| 2005 Q4 | -24.9 Million USD | 1.44% |
| 2005 FY | - USD | 30.74% |
| 2005 Q2 | -26.36 Million USD | -64.64% |
| 2005 Q1 | -16.01 Million USD | 48.64% |
| 2005 Q3 | -25.26 Million USD | 4.17% |
| 2004 Q2 | -57.26 Million USD | -90.55% |
| 2004 Q1 | -30.05 Million USD | -61.21% |
| 2004 FY | - USD | -175.7% |
| 2004 Q3 | -15.75 Million USD | 72.49% |
| 2004 Q4 | -31.18 Million USD | -97.91% |
| 2003 Q1 | -54.27 Million USD | -75.78% |
| 2003 FY | - USD | -30.86% |
| 2003 Q4 | -34.2 Million USD | -32.48% |
| 2003 Q3 | -30.17 Million USD | 35.64% |
| 2003 Q2 | -22.04 Million USD | -438.4% |
| 2002 Q3 | -31.85 Million USD | -74.86% |
| 2002 FY | - USD | -131.39% |
| 2002 Q4 | -12.42 Million USD | 183.35% |
| 2002 Q2 | -18.35 Million USD | -49.96% |
| 2002 Q1 | -12.06 Million USD | -109.81% |
| 2001 Q1 | 3.8 Million USD | 152.99% |
| 2001 Q2 | -5.1 Million USD | -256.56% |
| 2001 Q3 | 2.42 Million USD | 233.22% |
| 2001 Q4 | -5.55 Million USD | 1244.82% |
| 2001 FY | - USD | 548.0% |
| 2000 Q1 | -7.28 Million USD | -528.86% |
| 2000 Q3 | -6.11 Million USD | -2.26% |
| 2000 Q4 | -8.37 Million USD | -36.98% |
| 2000 FY | - USD | -901.97% |
| 2000 Q2 | -5.97 Million USD | 0.45% |
| 1999 Q4 | 200 Thousand USD | 151.85% |
| 1999 Q3 | -4.58 Million USD | -68.75% |
| 1999 Q2 | -1.3 Million USD | -148.48% |
| 1999 FY | - USD | -90.91% |
| 1999 Q1 | 3.43 Million USD | -42.11% |
| 1998 Q2 | 8.3 Million USD | -16.67% |
| 1998 Q4 | 6.6 Million USD | -65.45% |
| 1998 Q3 | 7.3 Million USD | 153.85% |
| 1998 Q1 | 7.8 Million USD | 56.0% |
| 1998 FY | - USD | 159.29% |
| 1997 FY | - USD | 976.92% |
| 1997 Q1 | 2.8 Million USD | 76.92% |
| 1997 Q2 | 3.1 Million USD | 47.83% |
| 1997 Q3 | 3.6 Million USD | -2.94% |
| 1997 Q4 | 6.5 Million USD | 51.52% |
| 1996 Q2 | -900 Thousand USD | 40.0% |
| 1996 Q3 | 1.3 Million USD | 360.0% |
| 1996 Q4 | 2 Million USD | -66.67% |
| 1996 FY | - USD | 113.54% |
| 1996 Q1 | -1.8 Million USD | -25.0% |
| 1995 Q1 | -1.8 Million USD | 53.33% |
| 1995 Q4 | -1.6 Million USD | 23.08% |
| 1995 Q3 | -2.4 Million USD | 7.14% |
| 1995 Q2 | -2.5 Million USD | -33.33% |
| 1995 FY | - USD | 19.33% |
| 1994 Q3 | -2.9 Million USD | -36.36% |
| 1994 Q2 | -2.2 Million USD | -10.0% |
| 1994 FY | - USD | -153.19% |
| 1994 Q1 | -2 Million USD | -66.67% |
| 1994 Q4 | -4 Million USD | -50.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q3 | -1.1 Million USD | 0.0% |
| 1993 Q4 | -1.2 Million USD | -9.09% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Agenus Inc. | -145.92 Million USD | 730.072% |
| Immix Biopharma, Inc. | -16.13 Million USD | 5798.105% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 704.182% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 917.021% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 341.974% |
| MiMedx Group, Inc. | 40.51 Million USD | -2169.235% |
| Novavax, Inc. | -487.39 Million USD | 288.643% |
| Seer, Inc. | -97.88 Million USD | 1039.292% |
| Acelyrin, Inc. | -381.52 Million USD | 340.986% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 3973.714% |
| IO Biotech, Inc. | -91.22 Million USD | 1107.833% |
| Ardelyx, Inc. | -55.35 Million USD | 1760.993% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 852.992% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 2169.069% |
| Fortress Biotech, Inc. | -133.64 Million USD | 787.972% |
| Fortress Biotech, Inc. | -133.64 Million USD | 787.972% |
| Geron Corporation | -174.78 Million USD | 626.042% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 623.377% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 1288.764% |
| Innoviva, Inc. | 248.96 Million USD | -269.307% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 11050.762% |
| ChromaDex Corporation | -3.89 Million USD | 23711.351% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | -803.817% |
| MEI Pharma, Inc. | 26.38 Million USD | -3385.315% |
| NextCure, Inc. | -59.03 Million USD | 1657.32% |
| Onconetix, Inc. | -36.7 Million USD | 2604.789% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | -41037.629% |
| GlycoMimetics, Inc. | -39.12 Million USD | 2450.151% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 804.968% |
| Vaxcyte, Inc. | -464.88 Million USD | 297.775% |
| Precigen, Inc. | -89.22 Million USD | 1130.446% |
| Pharming Group N.V. | 9.87 Million USD | -9208.758% |
| ContextLogic Inc. | -324 Million USD | 383.773% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 13455.985% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 1271.348% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 5514.44% |
| AlloVir, Inc. | -190.14 Million USD | 583.537% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 3913.163% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 832.628% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | 7135791.496% |
| Summit Therapeutics Inc. | 1 Million USD | -91750.749% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 499.851% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 2853.927% |
| Senti Biosciences, Inc. | -61.33 Million USD | 1598.999% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 655.81% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 3075.104% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | 286525.545% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 33514.475% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 1702.459% |
| Chimerix, Inc. | -92.97 Million USD | 1088.907% |
| PDS Biotechnology Corporation | -40.08 Million USD | 2393.693% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 4660.871% |
| CRISPR Therapeutics AG | -202.7 Million USD | 553.587% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 1663.916% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 678.077% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 4139.302% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 1088.439% |
| Precision BioSciences, Inc. | -32.04 Million USD | 2969.44% |
| Dyadic International, Inc. | -8.22 Million USD | 11271.995% |
| Elevation Oncology, Inc. | -41.46 Million USD | 2317.247% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | 316053.952% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | 13487.1% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 456.033% |
| Aptorum Group Limited | -9.59 Million USD | 9678.355% |
| Bicycle Therapeutics plc | -183.4 Million USD | 601.323% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 15131.784% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 4087.449% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 4717.355% |
| GT Biopharma, Inc. | 5.97 Million USD | -15277.588% |
| Alkermes plc | 495.04 Million USD | -85.724% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 1578.248% |
| Jaguar Health, Inc. | -33.13 Million USD | 2875.123% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 2933.1% |
| AbCellera Biologics Inc. | -192.15 Million USD | 578.474% |
| PureTech Health plc | -11.62 Million USD | 8007.68% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 5215.468% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 1151.65% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | -173704.537% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 1328.935% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 3913.163% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 1506.603% |
| AnaptysBio, Inc. | -143.16 Million USD | 742.219% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 2825.598% |
| ESSA Pharma Inc. | -26.45 Million USD | 3575.393% |
| Molecular Templates, Inc. | 1.43 Million USD | -64195.524% |
| Scopus BioPharma Inc. | -11.71 Million USD | 7949.52% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 270.287% |
| Vaxxinity, Inc. | -56.05 Thousand USD | 1640438.263% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 2061.986% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 3274.485% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 1394.529% |
| Structure Therapeutics Inc. | -102.45 Million USD | 997.36% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 1720.02% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 918.694% |
| ImmuCell Corporation | -2.5 Million USD | 36817.162% |
| Lantern Pharma Inc. | -15.78 Million USD | 5924.058% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 3242.477% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 9323.776% |
| Opthea Limited | -200.01 Million USD | 559.67% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 493.764% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 684.895% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 633.839% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 544.827% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -959.1% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 1895.088% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 9399.432% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 488.563% |
| Aptose Biosciences Inc. | -52.26 Million USD | 1859.061% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 953.348% |
| Soligenix, Inc. | -7.85 Million USD | 11808.182% |
| Century Therapeutics, Inc. | -121.2 Million USD | 858.552% |
| Kura Oncology, Inc. | -164.95 Million USD | 657.38% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 1247.876% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 9215.864% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | 96099.641% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 21437.34% |
| Autolus Therapeutics plc | -156.77 Million USD | 686.481% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 1186.06% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 1432.482% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 4712.351% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 585.767% |
| GRI Bio, Inc. | -10.89 Million USD | 8536.649% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 20460.585% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 850.515% |
| IGM Biosciences, Inc. | -253.35 Million USD | 462.896% |
| INmune Bio, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 985.835% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 2511.089% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 6097.206% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 5940.131% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 1717.426% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 958.45% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 445.653% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 574.08% |
| Verastem, Inc. | -83.16 Million USD | 1205.531% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 1918.053% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 681.077% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 905.885% |
| Histogen Inc. | -10.5 Million USD | 8853.937% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 6538.689% |
| Surrozen, Inc. | -41.13 Million USD | 2335.36% |
| Organovo Holdings, Inc. | -14.8 Million USD | 6309.82% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -28669248.301% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 1665.962% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 1892.463% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 4368.657% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 11126.93% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 653.65% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 1966.534% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 3904.626% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 6207.098% |
| Apollomics, Inc. | -171.74 Million USD | 635.337% |
| Amarin Corporation plc | -50.9 Million USD | 1906.284% |
| Mesoblast Limited | -61.33 Million USD | 1599.121% |
| Turnstone Biologics Corp. | -56.23 Million USD | 1735.0% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 742.053% |
| Synaptogenix, Inc. | -8.3 Million USD | 11167.412% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 6094.041% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 1558.318% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 19288.824% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | -214198.933% |
| Exelixis, Inc. | 196.6 Million USD | -367.659% |
| Better Therapeutics, Inc. | -38.26 Million USD | 2502.974% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 750.189% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 285.663% |
| NLS Pharmaceutics AG | -11.79 Million USD | 7894.616% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | -371812.012% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 3216.065% |
| Gritstone bio, Inc. | -126.86 Million USD | 824.739% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 1514.828% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 23085.96% |
| Avid Bioservices, Inc. | -11.48 Million USD | 8108.24% |
| Insmed Incorporated | -654.73 Million USD | 240.426% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | 40968.482% |
| MediWound Ltd. | -4.89 Million USD | 18890.64% |
| OmniAb, Inc. | -49.73 Million USD | 1948.799% |
| Alector, Inc. | -142.89 Million USD | 743.441% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 1176.183% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 1863.109% |
| Zai Lab Limited | -366.57 Million USD | 350.817% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 416.349% |
| Aura Biosciences, Inc. | -83.69 Million USD | 1198.53% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 508.182% |
| Immunic, Inc. | -99.11 Million USD | 1027.664% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 798.281% |
| Veracyte, Inc. | -49.4 Million USD | 1960.847% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 13115.784% |
| FibroGen, Inc. | -261.4 Million USD | 451.725% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 8352.634% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 13232.166% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 5012.286% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 36.566% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 3716.655% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | -2204.903% |
| TG Therapeutics, Inc. | 26.1 Million USD | -3422.705% |
| Galecto, Inc. | -37.51 Million USD | 2550.561% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 2502.786% |
| Fortrea Holdings Inc. | 167.3 Million USD | -449.567% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 784.708% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 3347.593% |
| XBiotech Inc. | -35.76 Million USD | 2670.67% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 1514.828% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 1509.082% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 980.213% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 3681.435% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 2349.801% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 278.027% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 1741.217% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 890.326% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 4247.246% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 491.139% |
| NexImmune, Inc. | -28.16 Million USD | 3364.137% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 16739.544% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 7896.852% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 80.245% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 3720.928% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 830.596% |
| Ainos, Inc. | -8.77 Million USD | 10580.061% |
| Pluri Inc. | -20.22 Million USD | 4645.988% |
| Prothena Corporation plc | -190.1 Million USD | 583.634% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 817.192% |
| Celularity Inc. | -183.94 Million USD | 599.835% |
| Rallybio Corporation | -72.37 Million USD | 1370.399% |
| Cue Biopharma, Inc. | -46.05 Million USD | 2096.495% |
| MeiraGTx Holdings plc | -57.05 Million USD | 1711.558% |
| Omeros Corporation | -163.61 Million USD | 661.962% |
| Humacyte, Inc. | -96.45 Million USD | 1053.188% |
| Immunocore Holdings plc | -59.64 Million USD | 1641.394% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 4846.159% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 3873.552% |
| Blueprint Medicines Corporation | -474.61 Million USD | 293.722% |
| CalciMedica, Inc. | -34.18 Million USD | 2789.245% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 1355.463% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 645.812% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 464.288% |
| Pulmatrix, Inc. | -12.64 Million USD | 7370.489% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 2889.013% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 1139.287% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 281.592% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 1008.389% |
| Cytokinetics, Incorporated | -456.68 Million USD | 301.327% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 2855.0% |
| Nutriband Inc. | -5.12 Million USD | 18051.309% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 2224.76% |
| Vor Biopharma Inc. | -114.37 Million USD | 903.898% |
| Roivant Sciences Ltd. | -996.51 Million USD | 192.264% |
| Evogene Ltd. | -23.2 Million USD | 4062.36% |
| ProKidney Corp. | -147.66 Million USD | 722.626% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 1524.694% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | 600447.374% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 262.596% |
| CorMedix Inc. | -48.88 Million USD | 1980.715% |
| BioLineRx Ltd. | -57.06 Million USD | 1711.304% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 922.694% |
| Galectin Therapeutics Inc. | -202 Thousand USD | 455261.386% |
| Atai Life Sciences N.V. | -36.31 Million USD | 2632.087% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 1256.264% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 1230.724% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 433.726% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 3090.976% |
| MediciNova, Inc. | -9.87 Million USD | 9405.959% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 830.045% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 60185.309% |
| GeoVax Labs, Inc. | -26.66 Million USD | 3547.576% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 508.65% |
| Biomea Fusion, Inc. | -124.62 Million USD | 837.784% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 378.327% |
| Mereo BioPharma Group plc | -26.05 Million USD | 3628.654% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 583.047% |
| Absci Corporation | -95.45 Million USD | 1063.183% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 3162.201% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 958.33% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 493.799% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 4122.866% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 542.381% |
| Allakos Inc. | -189.91 Million USD | 584.125% |
| Imunon, Inc. | -19.87 Million USD | 4725.28% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 947.46% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -748.774% |
| BioAtla, Inc. | -122.24 Million USD | 852.142% |
| NLS Pharmaceutics AG | -11.79 Million USD | 7894.616% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 5933.551% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 406.176% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 2318.317% |
| XOMA Corporation | -39.36 Million USD | 2435.821% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 1026.336% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 881.493% |
| aTyr Pharma, Inc. | -52.17 Million USD | 1862.095% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 1196.971% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 718.596% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 491.971% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 6834.242% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 11532.376% |
| Akari Therapeutics, Plc | -16.8 Million USD | 5572.122% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -487126.691% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | -103.437% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 14491.61% |
| UroGen Pharma Ltd. | -63.83 Million USD | 1540.407% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 1453.789% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 12759.018% |
| Orgenesis Inc. | -60.71 Million USD | 1614.256% |
| Entera Bio Ltd. | -8.8 Million USD | 10543.276% |
| GH Research PLC | -41.15 Million USD | 2334.165% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 3702.908% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 1218.074% |
| Xencor, Inc. | -125.87 Million USD | 830.434% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | 64551.244% |
| Replimune Group, Inc. | -230.19 Million USD | 499.407% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 4661.184% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 8502.723% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 14491.61% |
| Portage Biotech Inc. | -18.19 Million USD | 5152.069% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 60185.309% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 979.127% |
| OncoCyte Corporation | -23.12 Million USD | 4076.24% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 8236.253% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 8125.128% |
| Purple Biotech Ltd. | -22.22 Million USD | 4236.9% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 14443.619% |
| scPharmaceuticals Inc. | -46.06 Million USD | 2096.105% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 5262.507% |
| HilleVax, Inc. | -132.46 Million USD | 794.085% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 8746.911% |
| Tharimmune, Inc. | -9.3 Million USD | 9983.55% |
| Genprex, Inc. | -31.06 Million USD | 3060.107% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 590.293% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 3032.404% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | 120443.717% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | -609178.747% |
| OKYO Pharma Limited | -15.74 Thousand USD | 5839256.553% |
| Savara Inc. | -59.13 Million USD | 1654.844% |
| Curis, Inc. | -45.13 Million USD | 2136.877% |
| Daré Bioscience, Inc. | -30.7 Million USD | 3094.725% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 6152.38% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 12932.184% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 3539.164% |
| BeiGene, Ltd. | -1.12 Billion USD | 181.755% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 5740.235% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 313.531% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 1117.74% |
| Erasca, Inc. | -121.31 Million USD | 857.914% |
| bluebird bio, Inc. | -167.16 Million USD | 650.024% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 20537.339% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -196.318% |
| DBV Technologies S.A. | -85.98 Million USD | 1169.324% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 20537.339% |
| Moderna, Inc. | -3.28 Billion USD | 128.006% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 2257.821% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 16378.789% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 1636.166% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 381.82% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 770.678% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 2041.11% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 761.296% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 546.627% |
| MacroGenics, Inc. | 2.01 Million USD | -45483.837% |
| RenovoRx, Inc. | -11.39 Million USD | 8172.221% |
| Adicet Bio, Inc. | -136.53 Million USD | 773.399% |
| Prime Medicine, Inc. | -193.75 Million USD | 574.52% |
| Aditxt, Inc. | -25.45 Million USD | 3711.546% |
| Adagene Inc. | -14.95 Million USD | 6249.684% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 12677.478% |
| Quantum-Si incorporated | -91.8 Million USD | 1101.51% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | -29.059% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | -627.078% |
| SciSparc Ltd. | -5.28 Million USD | 17506.778% |
| Vericel Corporation | 2.86 Million USD | -32002.863% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 965802.462% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 4338.66% |
| Generation Bio Co. | -133.3 Million USD | 789.742% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 1207.342% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 1168.814% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 504.261% |
| Invivyd, Inc. | -196.61 Million USD | 567.628% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 345.735% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 10013.165% |
| Spero Therapeutics, Inc. | 27.15 Million USD | -3285.969% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 9039.485% |
| 2seventy bio, Inc. | -206.41 Million USD | 545.419% |
| ADMA Biologics, Inc. | 5.12 Million USD | -17857.539% |
| Clene Inc. | -43.24 Million USD | 2226.283% |
| Capricor Therapeutics, Inc. | -23 Million USD | 4095.945% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 1996.623% |
| GeoVax Labs, Inc. | -26.66 Million USD | 3547.576% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 406.919% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 2603.246% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | -3800.335% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | -18624.608% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 2930.571% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 680.431% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 234.359% |
| Evaxion Biotech A/S | -21.4 Million USD | 4395.781% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 1484.365% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 522.396% |
| Trevena, Inc. | -35.28 Million USD | 2705.492% |
| Surrozen, Inc. | -41.13 Million USD | 2335.36% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 1255.174% |
| Cingulate Inc. | -22.95 Million USD | 4105.859% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 12423.093% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 2566.073% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 11276.569% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 999.053% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 1455.546% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 1675.115% |
| Clearmind Medicine Inc. | -8.71 Million USD | 10655.179% |
| Kronos Bio, Inc. | -121.83 Million USD | 854.679% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 1336.752% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 37759.569% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 1011.885% |
| Statera Biopharma, Inc. | 38.93 Million USD | -2261.441% |
| ImmunityBio, Inc. | -436.18 Million USD | 310.79% |
| Korro Bio, Inc. | -80.9 Million USD | 1236.441% |
| Kineta, Inc. | -15.71 Million USD | 5950.999% |
| BioVie Inc. | -31.95 Million USD | 2977.684% |
| Codexis, Inc. | -49.28 Million USD | 1965.605% |
| Celularity Inc. | -183.94 Million USD | 599.835% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 515.072% |
| Celcuity Inc. | -58.3 Million USD | 1676.791% |
| Virax Biolabs Group Limited | -6.6 Million USD | 14011.423% |
| Cibus, Inc. | -314.58 Million USD | 392.266% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| IN8bio, Inc. | -28.5 Million USD | 3325.603% |
| Kodiak Sciences Inc. | -259.02 Million USD | 454.959% |
| Annexon, Inc. | -141.57 Million USD | 749.427% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 916.549% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 1532.217% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 3388.95% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 499.733% |
| Eyenovia, Inc. | -24.1 Million USD | 3914.09% |
| Puma Biotechnology, Inc. | 44.78 Million USD | -1953.023% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 283873.457% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 1345.767% |
| Arcellx, Inc. | -64.14 Million USD | 1533.356% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 2142.533% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 844.619% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 3077.223% |
| Moolec Science SA | -52.07 Million USD | 1865.562% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 1881.626% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 2374.85% |
| Royalty Pharma plc | 1.88 Billion USD | 51.283% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 868.796% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 9960.585% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 4532.944% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 653.604% |
| Humacyte, Inc. | -96.45 Million USD | 1053.188% |
| 89bio, Inc. | -134.46 Million USD | 783.776% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 1265.675% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | -22590.671% |
| Genelux Corporation | -24.16 Million USD | 3904.784% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 2820.195% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 662.464% |
| Notable Labs, Ltd. | -14.4 Million USD | 6484.903% |
| Liquidia Corporation | -70.05 Million USD | 1412.509% |
| Mustang Bio, Inc. | -48.06 Million USD | 2012.96% |
| Immunovant, Inc. | -269.97 Million USD | 440.556% |
| Quantum-Si incorporated | -91.8 Million USD | 1101.51% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 1395.222% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 4861.891% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 1001.292% |
| Acasti Pharma Inc. | -11.3 Million USD | 8235.793% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 4231.65% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 6097.206% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 536.755% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 21630.495% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 5889.836% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 3295.114% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 2582.922% |
| PepGen Inc. | -83.58 Million USD | 1200.029% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 3216.276% |
| United Therapeutics Corporation | 1.38 Billion USD | 33.702% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 4115.487% |
| Solid Biosciences Inc. | -93.43 Million USD | 1084.038% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 19368.166% |
| Immuneering Corporation | -58.06 Million USD | 1683.557% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -28669248.301% |
| Silo Pharma, Inc. | -3.62 Million USD | 25454.985% |
| Belite Bio, Inc | -31.52 Million USD | 3016.128% |
| XOMA Corporation | -39.36 Million USD | 2435.821% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 1463.183% |
| Bionomics Limited | -9.83 Million USD | 9446.614% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 1194.75% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 2756.84% |
| uniQure N.V. | -253.1 Million USD | 463.266% |
| Cassava Sciences, Inc. | -95.68 Million USD | 1060.868% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 12677.478% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 809.96% |
| Forte Biosciences, Inc. | -32.47 Million USD | 2931.007% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 11520.77% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 3358.181% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 283873.457% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 8352.634% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 5882.19% |
| Altimmune, Inc. | -87.93 Million USD | 1145.575% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 1098.519% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 2756.84% |
| Compugen Ltd. | -12.51 Million USD | 7446.005% |
| Peak Bio, Inc. | -1356.23 USD | 67792878.511% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 1991.901% |
| Benitec Biopharma Inc. | -22.49 Million USD | 4188.155% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 479.453% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 3321.196% |
| Zura Bio Limited | -60.56 Million USD | 1618.132% |
| PolyPid Ltd. | -20.26 Million USD | 4637.462% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 5988.849% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 3321.196% |
| Instil Bio, Inc. | -146.12 Million USD | 729.218% |
| argenx SE | -216.02 Million USD | 525.615% |
| Immunome, Inc. | -28.27 Million USD | 3352.188% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 1996.78% |
| Verona Pharma plc | -52.46 Million USD | 1852.37% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 1070.145% |
| Shattuck Labs, Inc. | -87.61 Million USD | 1149.393% |
| CervoMed Inc. | -2.17 Million USD | 42433.303% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 852.124% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 7343.567% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 2008.552% |
| Moolec Science SA | -52.07 Million USD | 1865.562% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 5464.217% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 805.13% |
| Design Therapeutics, Inc. | -66.32 Million USD | 1486.243% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 1235.276% |
| NeurAxis, Inc. | -6.66 Million USD | 13895.884% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 2535.566% |
| Lumos Pharma, Inc. | -36.57 Million USD | 2614.154% |
| Achilles Therapeutics plc | -70.44 Million USD | 1405.224% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 1070.145% |
| 180 Life Sciences Corp. | -22.13 Million USD | 4253.903% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | -15672.638% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 37759.569% |
| Nutriband Inc. | -5.12 Million USD | 18051.309% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 937.761% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 1758.656% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 1918.845% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 1508.499% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 1799.181% |
| Palisade Bio, Inc. | -12.28 Million USD | 7586.573% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 2126.239% |
| Beam Therapeutics Inc. | -156.47 Million USD | 687.594% |
| Neurogene Inc. | -52.28 Million USD | 1858.455% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 773.622% |
| AEON Biopharma, Inc. | -48.36 Million USD | 2001.172% |
| Sesen Bio, Inc. | -50.84 Million USD | 1908.47% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 1222.182% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 7544.731% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 315.105% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 974.004% |
| Athira Pharma, Inc. | -116.7 Million USD | 887.834% |
| Vaccinex, Inc. | -19.74 Million USD | 4755.793% |
| HCW Biologics Inc. | -23.57 Million USD | 3999.83% |
| XOMA Corporation | -39.36 Million USD | 2435.821% |
| Nektar Therapeutics | -243.1 Million USD | 478.198% |
| Arvinas, Inc. | -394.8 Million USD | 332.884% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -487126.691% |
| Merus N.V. | -149.2 Million USD | 716.208% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 1083.448% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 3041.222% |
| Rezolute, Inc. | -68.42 Million USD | 1443.738% |
| Clene Inc. | -43.24 Million USD | 2226.283% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 6061.708% |
| BeyondSpring Inc. | -21.54 Million USD | 4368.459% |
| Synlogic, Inc. | -55.16 Million USD | 1766.804% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 7709.253% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 8739.598% |
| Peak Bio, Inc. | -1356.23 USD | 67792878.511% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 2932.053% |
| Krystal Biotech, Inc. | 17.9 Million USD | -5035.311% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 876.391% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 369.353% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 20059.613% |
| MannKind Corporation | 15.12 Million USD | -5977.242% |
| Ikena Oncology, Inc. | -74.39 Million USD | 1335.837% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 7401.088% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | -4423.176% |
| Gossamer Bio, Inc. | -172.15 Million USD | 634.078% |
| CohBar, Inc. | -12.06 Million USD | 7720.126% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 3704.32% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 3162.201% |
| Legend Biotech Corporation | -477.87 Million USD | 292.4% |
| Mural Oncology plc | -192.72 Million USD | 577.079% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 906.132% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 5794.708% |
| Disc Medicine, Inc. | -91.02 Million USD | 1110.081% |
| Champions Oncology, Inc. | -5.05 Million USD | 18292.046% |
| REGENXBIO Inc. | -239.46 Million USD | 483.952% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 8678.186% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 1749.017% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 2471.594% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 915.051% |
| Vaxart, Inc. | -74.72 Million USD | 1330.446% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 2711.39% |
| Cellectis S.A. | -98.09 Million USD | 1037.281% |
| Longeveron Inc. | -20.06 Million USD | 4683.38% |
| Repare Therapeutics Inc. | -114.27 Million USD | 904.587% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 309.343% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 1328.982% |
| Revolution Medicines, Inc. | -430.58 Million USD | 313.531% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 14719.59% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 3086.216% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 1332.64% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | -18652.315% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 8485.098% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 80.035% |
| Denali Therapeutics Inc. | -179.97 Million USD | 610.869% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 965802.462% |
| Veru Inc. | -89.97 Million USD | 1121.862% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 3520.738% |
| Cingulate Inc. | -22.95 Million USD | 4105.859% |
| Passage Bio, Inc. | -98.34 Million USD | 1034.937% |
| Context Therapeutics Inc. | -25.06 Million USD | 3768.815% |
| Exicure, Inc. | -15.53 Million USD | 6016.893% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 546.185% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 2586.548% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 15519.894% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 645.77% |
| Nuvalent, Inc. | -149.49 Million USD | 715.034% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 11405.695% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 1170.419% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 3146.676% |
| OmniAb, Inc. | -49.73 Million USD | 1948.799% |
| Anew Medical, Inc. | -1.3 Million USD | 70779.407% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 7536.315% |
| Lipocine Inc. | -16.32 Million USD | 5732.818% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 1479.07% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 1337.401% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 2511.089% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 2456.657% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 4244.732% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 268.68% |
| Ocugen, Inc. | -64.82 Million USD | 1518.276% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 1093.222% |
| Q32 Bio Inc. | -86.5 Million USD | 1162.896% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 5531.713% |
| Alumis Inc. Common Stock | -156.89 Million USD | 686.032% |
| Equillium, Inc. | -12.13 Million USD | 7674.773% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 1672.421% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 11733.372% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 4974.754% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 2069.13% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 964.569% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 5240.309% |
| Dominari Holdings Inc. | -22.44 Million USD | 4197.264% |
| Edesa Biotech, Inc. | -8.19 Million USD | 11326.008% |
| vTv Therapeutics Inc. | -25.41 Million USD | 3718.078% |
| Bio-Techne Corporation | 326.66 Million USD | -181.46% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 338.896% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | -324.895% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 801.274% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 2556.322% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 708.484% |
| Nkarta, Inc. | -120.48 Million USD | 863.129% |
| BioCardia, Inc. | -11.56 Million USD | 8053.512% |
| Iterum Therapeutics plc | -34.58 Million USD | 2758.837% |